Watch this on-demand webcast of a live CCO presentation on distinguishing tardive dyskinesia from drug-induced parkinsonism and why it is important to treat sooner rather than later.
The presentation will focus on tardive dyskinesia, clinical pearls to distinguish it from other drug-induced movement disorders, and how assessment of the impact of tardive dyskinesia can aid treatment decisions with first-line VMAT2 inhibitor therapy.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.